Cidara Therapeutics 2025 Q3 Earnings Net Loss Widens 420.7%

viernes, 7 de noviembre de 2025, 1:40 am ET1 min de lectura
CDTX--

Cidara Therapeutics (CDTX) reported Q3 2025 earnings with a GAAP EPS of -$3.10, . , . , CidaraCDTX-- remains revenue-free, underscoring its heavy R&D investment. CEO Jeff Stein emphasized accelerating clinical trials and partnerships to offset ongoing financial challenges.

Revenue

.

Earnings/Net Income

. Meanwhile, , . . , .

Price Action

, , .

Post-Earnings Price Action Review

. . , , . . , , , . , , . , , . . , , , . . , . . , . , , . , .

, , , , ,

Additional News

. , . , . , , , . .

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios